Scientists believe they have discovered a special antibody which may lead to a treatment for Retinitis Pigmentosa, a condition that causes loss of central vision, as well as night and color vision. A ...

Please provide your email address to receive an email when new articles are posted on . VANCOUVER, British Columbia — QLT's phase 1b proof-of-concept trial of its treatment for retinitis pigmentosa ...

Please provide your email address to receive an email when new articles are posted on . Electrical stimulation might help to slow disease progression and restore visual field in patients with ...

STOCKHOLM — Trial results are demonstrating the safety and effectiveness of a novel gene modifier therapy for treating retinitis pigmentosa associated with NR2E3 and RHO mutations. Researchers ...

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health ®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), ...

Participants are being enrolled in the first clinical trial that tests the use of retinal progenitor cells to treat retinitis pigmentosa, reported project director Dr. Henry Klassen of UCI's Gavin ...

According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...

Neuropathy, ataxia and retinitis pigmentosa, also known as NARP syndrome, is a rare genetic condition characterized by numerous signs and symptoms which affect the nervous system. People with NARP ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has announced positive results from its ongoing clinical trials for VP-001, a treatment for the childhood blinding disease ...

Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of its developmental retinitis pigmentosa (RP) treatment, jCell. The company is recruiting 70 patients ...

Retinitis pigmentosa is a devastating diagnosis. This condition can leave optometrists and ophthalmologists scrambling as they attempt to explain possible treatment options, none of which are very ...